Authors


Teja Ghanta, PharmD

Latest:

Addressing Neonatal CNS Infections: Case Report of Ceftaroline Therapy in Preterm Infant With Ventriculosubgaleal Shunt

Here is a novel use of ceftaroline to treat methicillin-resistant Staphylococcus epidermidis ventriculitis in a preterm infant with a ventriculosubgaleal shunt.


Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS

Latest:

COVID-19 Booster Shots and the Future

Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.



Jeff Fischer, MBA

Latest:

Longhorn Vaccines Develops Sepsis Vaccine Targeting Key Toxins

This composite peptide vaccine targets key bacterial toxins to prevent sepsis, enhance antibiotic efficacy, reduce inflammation in diseases and cancer, with further data expected soon.


Geraldine A. Finlay, MD

Latest:

Identifying Disparities in Sepsis Diagnosis for Unbiased Care

Risk of inaccuracy with pulse oximeters and clinician knowledge gaps in people of color may affect sepsis evaluations and impact treatment plans.



George Loukatos, MD

Latest:

Future Directions for Managing COVID-19 and Influenza

George Loukatos, MD, shares clinical pearls for the management of the SARS-CoV-2 and influenza viruses.


Subramanya Shyam Ganti, MD, MBBS

Latest:

Challenges in the Management of Mycobacterium abscessus Complex

This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.


Babafemi Taiwo, MBBS

Latest:

Cabotegravir Combined With Broadly Neutralizing Antibodies Maintains Undetectable HIV

In a long-acting dose regimen, an investigational antibodies treatment is a potent antiviral that can function as a component of a complete antiretroviral regimen.



Jennifer Cocohoba, PharmD

Latest:

Contemporary Issues on the Treatment of Women Living with HIV in the US

The increasing presence of multiple non-AIDS comorbidities in women and others living with HIV challenges clinicians to steer away from the approach of optimizing individual chronic conditions but to think more holistically.


Paul Monach, MD, PhD

Latest:

From Pandemic to Endemic

A research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.


Karrine D. Brade, PHARMD, BCPS AQ-ID, BCIDP

Latest:

So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?

Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.


Mary Joyce B. Wingler PHARMD, BCIDP

Latest:

The ART of Implementing an Antiretroviral Stewardship Program

By addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.


Morgan Petronelli

Latest:

cUTI Roundtable: The Latest Therapeutic Developments

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.


Monica Verduzco-Gutierrez, MD

Latest:

What We Know But Still Have to Learn About Long COVID

Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.


Caitlin Soto, PharmD, BCIDP

Latest:

A Long-Acting Injectable for the Treatment of Candida spp Infections

In the second installment of a 3-part series on long-acting injectables related to various infections, Caitlin Soto, PharmD, BCIDP, provides insights on using rezafungin for invasive candidiasis.



T. Sam Albanesi, MD, MA

Latest:

An Update on Lenacapavir

This new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.


Jessica Malaty Rivera, MS

Latest:

mRNA COVID-19 Vaccines and Turbo Cancer: The Latest Myth That Won’t Disappear

The continuation of misinformation and disinformation being disseminated in the public is causing more public health communication issues as mistruths associate the vaccines with cancer.


Nisha Patel, PharmD, BCPS

Latest:

To Prophylax or not to Prophylax: Preventing CDI

Clinicians look at optimal approaches for trying to avoid Clostridioides difficile infection (CDI).


Jenna Salay, BS

Latest:

What's New In 2024: From the CLSI Subcommittee on Antimicrobial Susceptibility Testing

The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.


Alison L. Blackman, PharmD, BCIDP

Latest:

So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?

Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.


Ashley L. O’Leary, PHARMD, AAHIVP

Latest:

Outpatient Antimicrobial Stewardship: The Keys to Developing a Successful Program

This form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.


Brandon Dionne, PharmD, BCPS-AQ ID, BCIDP, AAHIVP

Latest:

Going Viral on Social Media: Integrating Digital Tools into Pharmacy Rotations

In the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.


Jesse S. Veisblatt, MD

Latest:

Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022

Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.


Joseph Zackular, PhD

Latest:

While Hospital-Acquired C difficile Cases Have Decreased, Community-Acquired Cases Have Risen

Joseph Zackular, PhD highlights targeting high-risk groups for vaccination and shares insights into the future of mRNA vaccine development for C diff.


Dana Holger, PharmD, MPH, AAHIVP

Latest:

Tricky Infusion Issues and Potential Solutions: OPAT Edition

Outpatient parenteral antimicrobial therapy (OPAT) offers benefits for patients as well as providing cost effectiveness; however, it is not without its challenges. Two clinicians provide insights on this modality.



Emily Jenkins PhD, DVM, BScHon

Latest:

Will the Melting Permafrost Uncover Vector Borne and Zoonotic Pathogens and Release Ancient Infectious Diseases?

With melting ice and the release of ancient viruses, there are concerns around the emergence of potentially unknown infectious diseases. Emily Jenkins PhD, DVM, BScHon, offers insights on “zombie viruses” and says polar bears might hold the key to understanding what lies ahead, and how a One Health approach may help in surveillance and prevention.

© 2025 MJH Life Sciences

All rights reserved.